Monograph Details
|
|
Urogenital System
> Urinary tract disorders
|
|
HIPREX |
| Manufacturer |
|
Sanofi Aventis |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Antiseptic. |
| Generic Name |
|
Methenamine hippurate 1 g; tabs; contains tartrazine. |
| Indications |
|
Prophylaxis and suppression of recurrent UTIs. |
| Children |
|
<6 years: not recommended. ≥6 years: 0.5–1 g twice daily. |
| Adults |
|
1 g twice daily. |
| Contraindications |
|
Renal or hepatic insufficiency. Severe dehydration. As sole therapy in infections with systemic involvement. |
| Precautions |
|
Maintain acid urine. Monitor therapy and liver function with repeated urine cultures. Aspirin allergy. Pregnancy. |
| Interactions |
|
Sulfonamides precipitate with formaldehyde in urine; avoid concomitant use. |
| Adverse Reactions |
|
Nausea, dysuria, rash, bladder irritation, albuminuria, hematuria, elevated transaminases. |
| How Supplied |
|
Tabs—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
